← Back

China Meheco Co Ltd

China Meheco Group Co., Ltd. operates in the pharmaceutical industry in China and internationally. It engages in international trade of pharmaceuticals, including preparations, drug substances, intermediates, medical devices, consumables, Chinese medicinal materials, and extracts, as well as pharmaceutical commerce. The company also provides supply chain services such as sales agency, logistics, warehousing, equipment bidding, repair and maintenance, clinical value promotion, and SPD services for areas including vascular interventional therapy, orthopedic implantation, neurosurgery, electrophysiology, ophthalmology, and stomatology. Founded in 1983 and based in Beijing, its drug products cover therapeutic fields such as anti-infection, cardiovascular and cerebrovascular, hormones and endocrine regulation, respiratory and digestive systems, nutritional supplements, and antipyretic and analgesics, as well as Chinese herbal materials and prepared slices.

Price · split & dividend adjusted
News & notes moving 600056.CG
600056.CG

China Meheco Appoints Zhang Lin as Board Secretary

China Meheco Group Co., Ltd. announced on September 7, 2026 that its tenth board of directors approved at its seventh meeting the appointment of Ms. Zhang Lin as board secretary, with a term from the date of the board resolution until the end of the tenth board's tenure. Ms. Zhang Lin is 41 years old, holds a master's degree, is a certified public accountant, and holds ACCA qualification. She previously worked at the Beijing office of PricewaterhouseCoopers. Since 2017, she has served successively as deputy director of the board office, securities affairs representative, deputy general manager of the finance department, general manager, and employee supervisor. She currently serves as assistant to the general manager and general manager of the strategic operations department. The announcement shows that Ms. Zhang Lin does not concurrently serve as general manager, deputy general manager in charge of business operations, or chief financial officer, and has sufficient time and energy to independently perform the duties of board secretary. Both the nomination committee and the board of directors have approved her qualification review.
600056.CG
Jiemian·12dRead more →
600056.CG▼5

China Meheco's 2026 interim net profit was 249 million yuan, down 15.26% year on year

China Meheco released its 2026 interim report. Total operating revenue was 16.952 billion yuan, a decrease of 124 million yuan from the same period last year, down 0.73% year on year. Net profit attributable to the parent company was 249 million yuan, a decrease of 44.8481 million yuan from the same period last year, down 15.26% year on year. Net cash flow from operating activities was negative 863 million yuan, a decrease of 317 million yuan from the same period last year. The company's latest asset-liability ratio was 62.69%, gross margin was 10.86%, achieving three consecutive quarters of growth, ROE was 2.08%, and diluted earnings per share was 0.17 yuan. The number of shareholders was 124,600, and the top ten shareholders held 54.05% of the total share capital.
600056.CG ▼
Jiemian·24dRead more →
600056.CG▲

China Meheco Subsidiary Tianfang Pharmaceutical Approved as Marketing Authorization Holder for Bumetanide Injection

China Meheco announced that its wholly-owned subsidiary Tianfang Pharmaceutical has received the Drug Supplementary Application Approval Notice for Bumetanide Injection issued by the National Medical Products Administration. The marketing authorization holder for this drug has been changed from Shenzhen Glein Biomedical Technology to Tianfang Pharmaceutical, with the drug approval number remaining unchanged. The production site, formulation, manufacturing process, and quality standards remain consistent with the original drug. Bumetanide Injection is used to treat edema associated with congestive heart failure, hypertension, liver disease, and kidney disease.
600056.CG ▲
Jiemian·61dRead more →
600056.CG▲

China Meheco Subsidiary Receives Marketing Approval for Ezetimibe API

China Meheco's wholly-owned subsidiary, Tianfang Pharmaceutical, has received the approval notification for the marketing application of ezetimibe chemical active pharmaceutical ingredient from the National Medical Products Administration. This API is mainly used for primary hypercholesterolemia, homozygous familial hypercholesterolemia, and homozygous sitosterolemia. The company stated that this approval will further expand its product portfolio and improve the layout of cardiovascular APIs. However, drug sales are subject to national policies and market conditions, and there are uncertainties. Investors are reminded to be aware of the risks.
600056.CG ▲
Jiemian·65dRead more →
© 2026 MarketDXAsset